Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acquired Complete Obliteration of the Vaginal Canal-Surgical Techniques for Management.

International urogynecology journal·2026
Same author

Cost-Effectiveness of Antibiotics in Sacral Neuromodulation.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Histological study to assess CO<sub>2</sub> laser therapy for the treatment of vaginal atrophy.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

OnabotulinumtoxinA: Dilution, Injection Depth/Number, and Trigone Inclusion.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Neurogenic Lower Urinary Tract Dysfunction in Women With Multiple Sclerosis.

Urogynecology (Philadelphia, Pa.)·2026
Same author

Author's Reply to: "Letter to the Editor Regarding Factors Associated with Placing High Value on the Uterus Among Women With Benign Gynecologic Conditions".

Journal of minimally invasive gynecology·2026

Related Experiment Video

Updated: May 19, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Beta-3 Agonists Versus Anticholinergics: A Cost-effectiveness Analysis.

Brad St Martin1, Shannon L Wallace2, Lauren A Cadish3

  • 1Department of Urogynecology, Hartford Healthcare, Hartford, CT.

Urogynecology (Philadelphia, Pa.)
|May 18, 2026
PubMed
Summary
This summary is machine-generated.

Beta-3 agonists are a cost-effective treatment for overactive bladder (OAB), reducing dementia risk and overall healthcare costs compared to anticholinergics. This makes them a dominant strategy for OAB management.

Related Experiment Videos

Last Updated: May 19, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

Area of Science:

  • Pharmacoeconomics
  • Geriatric Medicine
  • Urology

Background:

  • Overactive bladder (OAB) treatments include beta-3 agonists and anticholinergics.
  • Anticholinergics are associated with an increased risk of dementia.
  • The cost-effectiveness of OAB treatments, considering dementia risk, is not well-established.

Purpose of the Study:

  • To compare the 10-year costs, quality of life, and cost-effectiveness of beta-3 agonists versus anticholinergics for OAB.
  • To evaluate the impact of dementia risk on treatment decisions.
  • To determine the dominant treatment strategy for OAB.

Main Methods:

  • A Monte Carlo microsimulation model with 10,000 patients.
  • Modeled treatment pathways including second-line, third-line, and discontinuation.
  • Inputs derived from national databases and published literature; quality-adjusted life-years (QALYs) and costs were modeled.

Main Results:

  • Anticholinergic use led to an additional 1.9% incidence of dementia and $250,092 per patient over 10 years.
  • Beta-3 agonists were cost-effective (ICER=$9,132.26/QALY).
  • Beta-3 agonists were the dominant strategy, yielding higher QALYs and lower costs in 35.9% of patients.

Conclusions:

  • Beta-3 agonists offer a cost-effective OAB treatment strategy with reduced dementia risk.
  • Despite higher initial medication costs, overall OAB treatment costs are comparable over 10 years.
  • Increased access to beta-3 agonists can mitigate dementia-related risks and costs.